Abstract:Abstract Abstract 3054 Background: Disease relapse, major infection and graft-versus-host disease (GVHD) are the leading causes of death following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Donor T lymphocytes play a critical role in alloimmune recognition and their ability to detect non-self-antigens can lead to GVHD or contribute to prevention of relapse and infection. Three effector pathways have been described for T-cell cytotoxicity: granzyme B/perforin, Fas/Fas ligand (FasL) and secreted molecules such as tumor necrosis factor (TNF)-alpha. Granzyme B is a proapoptotic serine protease. Fas is widely expressed in immunocompetent cells and non-lymphoid tissues. FasL is mainly expressed on activated cytotoxic T lymphocytes (CTLs). When CTLs recognize target cells, they become activated and express FasL which induces apoptosis of target cells. The Fas gene has been found to be silenced in many tumor types. The importance of those effector pathways for the development of acute GVHD (aGVHD) has been well established. In our previous study, we have reported donor and/or recipient TNF-alpha gene polymorphism influenced on the risk of aGVHD. Recently several important polymorphisms have been identified in granzyme B, Fas, and FasL genes and reported to be relevant to allograft rejection in solid organ transplant patients. However, such information is less available in allo-HSCT. This present study was designed to investigate the influence of donor and recipient genetic variations of effector pathway molecules on the abilities of T-cell alloimmune responses including GVHD, cytomegalovirus (CMV) infection within 100 days and disease relapse following allo-HSCT. Methods: The entire study population consisted of 138 pairs of recipients and their unrelated donors, who underwent HSCT in our Center from January 2001 to March 2009. Genomic DNA was extracted from peripheral blood samples obtained from recipients and donors before transplantation. Five single nucleotide polymorphisms (SNPs) including granzyme B +55(A/G), -295(C/T), Fas -1377(G/A), -670(T/C) and FasL -844 (T/C) were analyzed. Results: (1) Patients receiving stem cells from a donor with granzyme B +55 AA genotype developed aGVHD more frequently than those with mutated allele (AG or GG), which has been reported to be associated with low-producing of granzyme B by CTLs and incapable of inducing apoptosis. Multivariate analysis confirmed that donor with the granzyme B +55 AA genotype was an independent risk factor for aGVHD (RR=1.545, 95%CI: 1.012–2.357, P=0.044). (2) Donor with FasL -844 TT genotype, a genotype reported to a reduction in the expression of FasL on T cells, conferred protection against the risk of aGVHD (RR=2.981, 95% CI: 1.320–6.736, P=0.009), however was an independent risk factor for early CMV infection (RR: 3.658, 95% CI: 1.534–8.722, P=0.003). Patients experiencing aGVHD have a higher risk of developing early CMV infection (RR=1.931, 95% CI: 1.242–3.003, P=0.003), early CMV infection also was a significant factor impacting aGVHD (RR=1.630, 95%CI: 1.294–2.053, P<0.001). (3) Recipient with Fas -670 C- allele positive, a mutated allele with higher Fas expression, was associated with a significantly lower risk of relapse (RR=3.453, 95% CI: 1.699–7.091, P=0.001) as well as superior overall survival (84.2% vs 21.2%, P<0.001) in patients with acute myeloid leukemia (AML), but not in patients with other myelogenous or lymphoid malignancies. The polymorphic sites granzyme B -295(C/T), Fas -1377(G/A), did not correlate with the T-cell alloimmune reactivities. Conclusions: Genetic variation, other than HLA polymorphism, regulating the immune response may influence outcomes of patients undergoing allo-HSCT. Transplant patients would thus benefit from accurate risk assessment and individualization of immunosuppressive therapy, taking into account donor and recipient genetic data, as well as other risk factors. This study is the first report of relationship between donor or recipient genetic variations of effector pathway molecules and the abilities of T-cell alloimmune responses. According to our results, special targeting granzyme B and Fas/FasL pathways may be a promising therapeutic strategy in patients with aGVHD, CMV infection and leukemia relapse after allo-HSCT at least in AML patients harboring Fas -670 wild-type genotype. Disclosures: No relevant conflicts of interest to declare.

Differential regulation of CCR5 expression on T lymphocytes in healthy donors after mobilization with rhG-CSF and its correlation with aGVHD]

Differential Regulation of Chemokine Receptor Expressions on T Lymphocyte Subsets in Healthy Donors after Mobilization with Rhg-CSF and Its Correlation with Acute GvHD

Alterations of CCR5 and CCR7 Expression on Donor Peripheral Blood T Cell Subsets after Mobilization with Rhg-Csf Correlate with Acute Graft-Versus-host Disease.

Down Regulation Of Cxc Chemokine Receptor 3 Impedes The Ability Of Anti-Cxcr3 Antibody To Block Graft-Versus-Host Disease

[Comparison of CCR5 Expression on T Lymphocytes Between the Bone Marrow and Peripheral Blood Grafts after Mobilization].

Genetic Variation In The Effector Pathways Of Cytotoxic T Lymphocytes Influences Alloimmune Reactivities Following Allogeneic Hematopoietic Stem Cell Transplantation

G-Csf Affects the Distribution and Clonality of Trgv and Trdv Repertoire of T Cells and the Expression Pattern of Cd3 Genes

[Influence of G-CSF Mobilization on Functions of Donor T Lymphocyte Subpopulation and Acute Graft-Versus-host Disease].

Granulocyte Colony-Stimulating Factor Affects the Distribution and Clonality of TRGV and TRDV Repertoire of T Cells and Graft-Versus-host Disease

Granulocyte Colony-Stimulating Factor Mobilization Affects the Expression of Regulatory Γδ T Cells

Regulatory Γδ T Cells Induced by G-CSF Participate in Acute Graft-Versus-host Disease Regulation in G-CSF-mobilized Allogeneic Peripheral Blood Stem Cell Transplantation.

Association of Chemokine Receptor CCR5, CCR6 and CCR7 Expressions on T Lymphocyte Subsets in Recipients after Allo-HSCT with Acute GvHD

Influence of Recombinant Human Granulocyte Colony Stimulating Factor (Rhg-Csf) on CD34+ Hematopoietic Stem Cells and Regulatory T Cells in Healthy Donors

The Effect of G-CSF Mobilization on the Expression of Immunoregulatory-Associated Molecules and G-CSFR Gene in the Peripheral Blood Γδ+ T Cells

Recombinant Human Granulocyte Colony-Stimulating Factor Significantly Decreases the Expression of CXCR3 and CCR6 on T Cells and Preferentially Induces T Helper Cells to a T Helper 17 Phenotype in Peripheral Blood Harvests.

Effect of Granulocyte Colony-Stimulating Factor Mobilization on the Expression of Th1/Th2 Chemokines and Their Receptors

Association Between Mdscs and Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Effects of rhG-CSF mobilization on immunological characteristics of peripheral blood grafts and steady-state bone marrow

Investigation on related factors of CD 34+ cells in peripheral blood mobilization effect by G-SCF stimulation

Effects of Rhg-Csf Mobilization on Th17 Cells in Donors' Peripheral Blood and Bone Marrow Grafts

Effect of granulocyte colony-stimulating factor mobilization on the expression patterns, clonality and signal transduction of TRAV and TRBV repertoire.